Structure of CHK1 10-pt. mutant complex with macrocyclic LRRK2 inhibitor compound 12 ((10aS,13aS)-3-cyclopropyl-1-methyl-8-(trifluoromethyl)-3,4,10a,11,13a,14-hexahydro-10H,13H-9,5-(azeno)furo[3,4-k]pyrazolo[4,3-b][1,4,6,10]oxatriazacyclotridecine)

Protein Data Bank Japan2026-04-22 更新2026-04-25 收录

下载链接：

https://pdbj.org/mine/summary/10ia

下载链接

链接失效反馈

官方服务：

资源简介：

Structure of CHK1 10-pt. mutant complex with macrocyclic LRRK2 inhibitor compound 12 ((10aS,13aS)-3-cyclopropyl-1-methyl-8-(trifluoromethyl)-3,4,10a,11,13a,14-hexahydro-10H,13H-9,5-(azeno)furo[3,4-k]pyrazolo[4,3-b][1,4,6,10]oxatriazacyclotridecine) Descriptor: (10aS,13aS)-3-cyclopropyl-1-methyl-8-(trifluoromethyl)-3,4,10a,11,13a,14-hexahydro-10H,13H-9,5-(azeno)furo[3,4-k]pyrazolo[4,3-b][1,4,6,10]oxatriazacyclotridecine, Serine/threonine-protein kinase Chk1 Authors: Palte, R.L, Yu, E.C, Zhou, H. Deposit date: 2026-01-21 Release date: 2026-04-08 Last modified: 2026-04-22 Method: X-RAY DIFFRACTION (1.739 Å) Cite: Discovery of Potent, Selective, CNS-Penetrant Macrocyclic LRRK2 Inhibitors for the Treatment of Parkinson's Disease. J.Med.Chem., 69, 2026

创建时间：

2026-01-21